These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 35870472)

  • 81. Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology Group.
    Salzer WL; Jones TL; Devidas M; Dreyer ZE; Gore L; Winick NJ; Sung L; Raetz E; Loh ML; Wang CY; De Lorenzo P; Valsecchi MG; Pieters R; Carroll WL; Hunger SP; Hilden JM; Brown P
    Pediatr Blood Cancer; 2015 Mar; 62(3):414-8. PubMed ID: 25407157
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol.
    Hann I; Vora A; Harrison G; Harrison C; Eden O; Hill F; Gibson B; Richards S;
    Br J Haematol; 2001 Apr; 113(1):103-14. PubMed ID: 11328289
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [Lineage switch - conversion of acute lymphoblastic leukaemia to acute myeloid leukaemia in 4 years old girl].
    Szpecht D; Derwich K; Wachowiak J; Konatkowska B; Dworacki G
    Med Wieku Rozwoj; 2008; 12(4 Pt 2):1041-4. PubMed ID: 19531823
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).
    Schultz KR; Pullen DJ; Sather HN; Shuster JJ; Devidas M; Borowitz MJ; Carroll AJ; Heerema NA; Rubnitz JE; Loh ML; Raetz EA; Winick NJ; Hunger SP; Carroll WL; Gaynon PS; Camitta BM
    Blood; 2007 Feb; 109(3):926-35. PubMed ID: 17003380
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Vitamin supplement use among children with Down's syndrome and risk of leukaemia: a Children's Oncology Group (COG) study.
    Blair CK; Roesler M; Xie Y; Gamis AS; Olshan AF; Heerema NA; Robison LL; Ross JA;
    Paediatr Perinat Epidemiol; 2008 May; 22(3):288-95. PubMed ID: 18426524
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
    DiNardo CD; Schuh AC; Stein EM; Montesinos P; Wei AH; de Botton S; Zeidan AM; Fathi AT; Kantarjian HM; Bennett JM; Frattini MG; Martin-Regueira P; Lersch F; Gong J; Hasan M; Vyas P; Döhner H
    Lancet Oncol; 2021 Nov; 22(11):1597-1608. PubMed ID: 34672961
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group.
    Miller TP; Troxel AB; Li Y; Huang YS; Alonzo TA; Gerbing RB; Hall M; Torp K; Fisher BT; Bagatell R; Seif AE; Sung L; Gamis A; Rubin D; Luger S; Aplenc R
    Pediatr Blood Cancer; 2015 Jul; 62(7):1184-9. PubMed ID: 25760019
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Results of successive EORTC-CLG 58 881 and 58 951 trials in paediatric T-cell acute lymphoblastic leukaemia (ALL).
    Hofmans M; Suciu S; Ferster A; Van Vlierberghe P; Mazingue F; Sirvent N; Costa V; Yakouben K; Paillard C; Uyttebroeck A; Plantaz D; Plat G; Simon P; Millot F; Poirée M; van der Werff Ten Bosch J; Piette C; Minckes O; Rohrlich P; Girard S; Cavé H; Bertrand Y; De Moerloose B
    Br J Haematol; 2019 Sep; 186(5):741-753. PubMed ID: 31124581
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Acute lymphoblastic leukaemia therapy in Poland. A report from the Polish Children's Leukaemia/Lymphoma Study Group.
    Radwańska U; Michalewska D; Armata J; Balwierz W; Bogusławska-Jaworska J; Cyklis R; Derulska D; Kołecki P; Lastowska M; Newecka-Samól T
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(2):199-210. PubMed ID: 2475398
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Clinical management of Australian adolescents and young adults with acute lymphoblastic and myeloid leukemias: A national population-based study.
    White VM; Skaczkowski G; Pinkerton R; Coory M; Osborn M; Bibby H; Nicholls W; Orme LM; Conyers R; Phillips MB; Harrup R; Walker R; Thompson K; Anazodo A
    Pediatr Blood Cancer; 2018 Nov; 65(11):e27349. PubMed ID: 30039912
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Phase-specific risks of outpatient visits, emergency visits, and hospitalizations during Children's Oncology Group-based treatment for childhood acute lymphoblastic leukemia: A population-based study.
    Bassal M; Silva M; Patel S; Gibson PJ; Breakey VR; Athale U; Zabih V; Li Q; Pechlivanoglou P; Pole JD; Mittmann N; Sutradhar R; Gupta S
    Pediatr Blood Cancer; 2021 Oct; 68(10):e29141. PubMed ID: 34003566
    [TBL] [Abstract][Full Text] [Related]  

  • 92. A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114).
    Rheingold SR; Tasian SK; Whitlock JA; Teachey DT; Borowitz MJ; Liu X; Minard CG; Fox E; Weigel BJ; Blaney SM
    Br J Haematol; 2017 May; 177(3):467-474. PubMed ID: 28295182
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization.
    Winter SS; Dunsmore KP; Devidas M; Wood BL; Esiashvili N; Chen Z; Eisenberg N; Briegel N; Hayashi RJ; Gastier-Foster JM; Carroll AJ; Heerema NA; Asselin BL; Gaynon PS; Borowitz MJ; Loh ML; Rabin KR; Raetz EA; Zweidler-Mckay PA; Winick NJ; Carroll WL; Hunger SP
    J Clin Oncol; 2018 Oct; 36(29):2926-2934. PubMed ID: 30138085
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Worldwide comparison of survival from childhood leukaemia for 1995-2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries.
    Bonaventure A; Harewood R; Stiller CA; Gatta G; Clavel J; Stefan DC; Carreira H; Spika D; Marcos-Gragera R; Peris-Bonet R; Piñeros M; Sant M; Kuehni CE; Murphy MFG; Coleman MP; Allemani C;
    Lancet Haematol; 2017 May; 4(5):e202-e217. PubMed ID: 28411119
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Using electronic medical record data to report laboratory adverse events.
    Miller TP; Li Y; Getz KD; Dudley J; Burrows E; Pennington J; Ibrahimova A; Fisher BT; Bagatell R; Seif AE; Grundmeier R; Aplenc R
    Br J Haematol; 2017 Apr; 177(2):283-286. PubMed ID: 28146330
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Outcomes among pediatric patients with cancer who are treated on trial versus off trial: A matched cohort study.
    Schapira MM; Stevens EM; Sharpe JE; Hochman L; Reiter JG; Calhoun SR; Shah SA; Bailey LC; Bagatell R; Silber JH; Tai E; Barakat LP
    Cancer; 2020 Aug; 126(15):3471-3482. PubMed ID: 32453441
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children's Oncology Group.
    Getz KD; Sung L; Ky B; Gerbing RB; Leger KJ; Leahy AB; Sack L; Woods WG; Alonzo T; Gamis A; Aplenc R
    J Clin Oncol; 2019 Jan; 37(1):12-21. PubMed ID: 30379624
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Quality of life in pediatric acute myeloid leukemia: Report from the Children's Oncology Group.
    Nagarajan R; Gerbing R; Alonzo T; Johnston DL; Aplenc R; Kolb EA; Meshinchi S; Barakat LP; Sung L
    Cancer Med; 2019 Aug; 8(9):4454-4464. PubMed ID: 31190442
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial.
    Menne T; Slade D; Savage J; Johnson S; Irving J; Kearns P; Plummer R; Shenton G; Veal GJ; Vormoor B; Vormoor J; Billingham L
    BMJ Open; 2022 Mar; 12(3):e059872. PubMed ID: 35246426
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Treatment-related adverse events associated with a modified UK ALLR3 induction chemotherapy backbone for childhood relapsed/refractory acute lymphoblastic leukemia.
    Sun W; Orgel E; Malvar J; Sposto R; Wilkes JJ; Gardner R; Tolbert VP; Smith A; Hur M; Hoffman J; Rheingold SR; Burke MJ; Wayne AS
    Pediatr Blood Cancer; 2016 Nov; 63(11):1943-8. PubMed ID: 27437864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.